CLIC-2201 for relapsed or refractory B-cell cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a B-cell cancer that has come back or stopped responding to treatment.
- For the adult group (18 or older), you need a specific type of aggressive lymphoma. For the younger group (1 to 39), you need B-cell acute lymphoblastic leukemia (B-ALL).
- Your heart, kidneys, and liver must be working well enough (your doctor will run tests to check).
- You must not have a serious infection, active autoimmune disease, or graft-versus-host disease (GVHD) that requires treatment.
- You must be willing to have a tumor or bone marrow biopsy before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a gene-modified cell treatment called CLIC-1901 for people whose CD19-positive cancer has come back or did not respond to prior treatment. It may help shrink the cancer by targeting a protein called CD19 on cancer cells.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
This trial tests a new treatment called PIC1 for people with certain types of B-cell lymphoma that have come back after treatment or stopped responding. PIC1 is a type of immunotherapy that helps your immune system attack the cancer cells.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
Hear when a new Leukemia, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.